A5103260922- Sarcoma Diagnosis and Treatment
- Vascular Tumors and Angiosarcomas
- Cardiac tumors and thrombi
- Cancer Risks and Factors
- Lymphoma Diagnosis and Treatment
- Ovarian cancer diagnosis and treatment
- Reproductive Biology and Fertility
- Gastrointestinal Tumor Research and Treatment
- Tumors and Oncological Cases
- CAR-T cell therapy research
- Lung Cancer Treatments and Mutations
- Renal cell carcinoma treatment
- Soft tissue tumor case studies
- Breast Cancer Treatment Studies
- Economic and Financial Impacts of Cancer
- Medicinal Plant Pharmacodynamics Research
- Histone Deacetylase Inhibitors Research
- Bone health and treatments
- PI3K/AKT/mTOR signaling in cancer
- Breast Lesions and Carcinomas
- Soft tissue tumors and treatment
- Multiple Myeloma Research and Treatments
- Cancer, Hypoxia, and Metabolism
- Biosimilars and Bioanalytical Methods
- Palliative Care and End-of-Life Issues
Shaare Zedek Medical Center
2004-2023
Hebrew University of Jerusalem
2006-2023
Assaf Harofeh Medical Center
2018-2020
Fred Hutch Cancer Center
2018
Istituto Ortopedico Rizzoli
2018
Cancer Research Center
2018
Stanford University
2018
Stanford Medicine
2018
Hadassah Medical Center
2004-2017
The University of Texas MD Anderson Cancer Center
2009-2012
Background: Pazopanib is a multitargeted tyrosine kinase inhibitor approved for the treatment of patients with selective subtypes advanced soft tissue sarcoma (STS) who have previously received standard chemotherapy including anthracyclines. Data on efficacy in vascular sarcomas are limited. The main objective this study was to investigate activity pazopanib sarcomas.Patients and methods: A retrospective sarcomas, angiosarcoma (AS), epithelioid hemangioendothelioma (HE) intimal (IS) treated...
The optimal treatment for advanced leiomyosarcoma is still debated. Given histotype-specific prospective controlled data lacking, this study retrospectively evaluated doxorubicin plus dacarbazine, ifosfamide, and alone as first-line treatments advanced/metastatic treated at European Organization Research Treatment of Cancer Soft Tissue Bone Sarcoma Group (EORTC-STBSG) sites.The inclusion criteria were a confirmed histological diagnosis, between January 2010 December 2015, measurable disease...
Menorrhagia is a serious complication in young female oncology patients who suffer from severe thrombocytopenia during myelosuppressive treatment. To the authors' knowledge, little known regarding incidence of this or effectiveness possible therapies for its prevention.In retrospective clinical study, after thorough gynecologic evaluation, with regular menstrual cycles undergoing treatments received either depo-medroxyprogesterone acetate (DMPA), D-tryptophan-6-luteinizing hormone-releasing...
Abstract Background Myxoid liposarcoma (MLS) is a soft tissue sarcoma with adipocytic differentiation characterized by unique chromosome rearrangement, t(12;16)(q13;p11). The exact efficacy of chemotherapy in MLS has not been clearly established. Patients and methods We retrospectively analyzed the records 37 histologically confirmed patients who were treated at University Texas MD Anderson Cancer Center from January 2000 to December 2009 doxorubicin 75-90 mg/m 2 over 72 hours combined...
A named patient program (NPP) was designed to provide patients with advanced soft-tissue sarcoma (aSTS) access pazopanib, a multitargeted tyrosine kinase inhibitor. The SPIRE study retrospective chart review of participating patients.Eligibility criteria for the NPP and mirrored those pivotal phase-III study, PALETTE, which compared pazopanib placebo in ≥18 years aSTS whose disease had progressed during or following prior chemotherapy were otherwise unsuitable chemotherapy. Outcomes interest...
We have evaluated the feasibility of use neoadjuvant imatinib mesylate in management unresectable localized gastrointestinal stromal tumors. In a pilot experience, two patients with tumors were treated imatinib. Their treatment course and surgical outcomes are described. both cases, patient attained sufficient tumor regression to enable complete resection tumor. conclude that tumors, administration may facilitate subsequent curative intent.
Abstract: The long-term risks of in vitro fertilization (IVF) treatment remain unclear. This study was designed to determine breast cancer risk factors women who underwent IVF, and establish characteristics these tumors. Records 7,162 consecutive IVF at a single center between 1984 2002 were linked with the Israel Cancer Registry identify developed cancer. IVF-related parameters compared 28 patients had undergone (IVF BC) for whom complete data available 140 did not develop non-BC). Tumor 38...
Abstract Background Trabectedin and thioglitazones have been documented to induce adipocytic maturation in myxoid liposarcoma; we noted this our experience as well. Intriguingly, also encountered same phenomenon liposarcomas exposed various combinations of neoadjuvant doxorubicin ifosfamide systemic chemotherapy with preoperative radiation, where the pathological effects less characterized. We examined histological changes, including maturation, associated treatment patients liposarcoma...
Gastrointestinal stromal tumors (GISTs) are driven by gain-of-function mutations of KIT or PDGFRa. The introduction imatinib has significantly extended survival for patients. However, most patients develop resistances. Notch signaling is a conserved developmental pathway known to play critical role in the development several cancers, functioning as tumor promoter suppressor. Given that normal progenitor cell GIST, interstitial Cajal, characteristics similar those cells neuroendocrine origin,...
To explore the activity of pazopanib (P) + sirolimus (S) in patients who progressed after previous clinical benefit on pazopanib.Eight with progressing metastatic high grade soft tissue sarcoma (STS) whose disease advanced P following a response duration at least 4 months were offered re-challenge supplemented by off-label S and single patient chondrosarcoma was combination as compassionate treatment. Patients treated two centers: Hadassah Medical Center Tel Aviv Center. received oral...
Leiomyosarcoma is the second most frequent soft-tissue sarcoma. Tumor lymphocytic infiltration (TIL) and programed cell death ligand-1 (PD-L1) have been associated with prognosis in different malignancies while DNA mismatch-repair deficiency (MMR-D) has response to check-point inhibitors. In this pilot study, we sought examine TIL, PD-L1 (MMR) protein expression 11 leiomyosarcoma its association outcome as potential biomarkers for adjuvant treatment. Eleven primary archived-tissues were...
A limited number of chemotherapeutic agents have been found to be active against advanced soft‑tissue sarcomas (STSs), particularly that progressed following doxorubicin treatment. The aim this retrospective study was determine the response treatment with gemcitabine plus paclitaxel in patients STSs. data were collected on all non‑resectable STS who treated a fixed dose 700 mg/m2 combination 70 days 1 and 8 every 3 weeks. total 30 included, median age 56.4 years (range, 40‑70 years)....
11574 Background: LMS is one of the most common soft tissue sarcoma histotypes that may arise in any site body. In advanced disease, first line treatment still based on Do alone or combination. Previous retrospective data suggested limited activity ifosfamide (Sleijfer 2010), whereas Da showed interesting results series. DoDa, DI and regimens were retrospectively evaluated as LMS. Methods: Inclusion criteria: confirmed histological diagnosis, between 1/2010 12/2015, measurable disease...
Pazopanib is a tyrosine kinase inhibitor indicated for the treatment of renal cell carcinoma and soft tissue sarcoma. Despite high inter-patient variability in pharmacokinetic exposure, pazopanib administered at fixed dose 800 mg once daily (QD). Pharmacokinetic exposure linked to both efficacy toxicity. In this case report, we illustrate value therapeutic drug monitoring by describing two patients with adequate trough concentrations (Cmin) an eight times lower than standard dose. Patient A...
8084 Background: Patients (pts) with cancer who are not receiving chemotherapy (ctx) or radiotherapy (rtx) often develop anemia. A previous randomized, controlled trial evaluating the effect of recombinant human erythropoietin therapy vs placebo on transfusion (tfn) incidence in this pt population failed to show a significant reduction tfn requirements treated pts, relative control (Abels, 1991). This multicenter, controlled, 25-week (wk) study is closed enrollment (n = 298) and was designed...
A previously healthy 54-year-old woman presented with a two-week history of pelvic pain. On physical examination, she had limited movement, without tenderness in the bones. An initial radiographic survey skeletal bone showed multiple lytic lesions axial skeleton (Panel A, arrow), ribs, skull B, bilaterally pelvis, both femurs C, and humeri D, arrow). Blood tests normocytic normochromic anemia hematocrit 24.9 percent, along sedimentation rate 140 mm per hour. Calcium levels results...
e21508 Background: Pazopanib (P) is a multikinase inhibitor targeting the VEGF and PDGF receptors capable of controlling soft tissue sarcoma for several months. Acquired resistance to P usually leads chemotherapy resumption. We present case reversal acquired by addition an mTOR inhibitor. Methods: A 46 year old female, completed five cycles adjuvant treatment with epirubicin ifosfamide followed radiotherapy fully resected gluteal pleomorphic undifferentiated sarcoma. Ten months later, single...
Molecular portraits of numerous tumors have flooded oncologists with vast amounts data. In parallel, effective inhibitors central pathways shown great clinical benefit. Together, this promises potential benefits to otherwise end-stage cancer patients. Here, we report a service offering mutation detection archived samples using the ion Ampliseq panel coupled consultation. A multidisciplinary think tank consisting oncologists, molecular-biologists, genetic counselors, and pathologists...